The Predictive Value of Serum Uric Acid on Acute Kidney Injury following Traumatic Brain Injury
Table 1
Baseline characteristics of AKI patients and non-AKI patients.
Total ()
Non-AKI ()
AKI ()
Age (year)
43 (25-57)
41 (23-54)
47 (32-60)
0.010
Female (, %)
93 (24.87)
76 (25.76%)
17 (21.52%)
0.433
Prehospital time (hour)
1 (1-2)
1 (1-2)
1 (1-1)
0.028
Vital signs in admission
SBP (mmHg)
120 (105-138)
120 (106-138)
113 (102-133)
0.135
DBP (mmHg)
0.104
Heart rate (bpm)
100 (81-119.25)
98 (80-117)
107 (89-124)
0.015
Temperature (°C)
36.7 (36.5-37.1)
36.7 (36.5-37)
36.8 (36.4-37.5)
0.368
Respiratory rate
20 (16-22)
20 (16-23)
18 (15-22)
0.022
GCS in admission
6 (5-9)
7 (5-10)
5 (4-6)
<0.001
Shock (%)
116 (31.02%)
71 (24.07%)
45 (56.96%)
<0.001
Laboratory tests
WBC (109/L)
14.34 (10.33-19)
13.98 (10.35-18.92)
14.98 (10.15-20.17)
0.607
Platelet (109/L)
106.5 (68-171.25)
122 (76-180)
72 (44-111)
<0.001
Hemoglobin (g/L)
90 (76-110.25)
94 (79-112)
80 (71-96)
<0.001
Albumin (g/L)
<0.001
Glucose (mmol/L)
9.49 (7.04-13.14)
8.84 (6.68-12.53)
11.7 (8.9-16.77)
<0.001
Chlorine (mmol/L)
110.9 (105.58-118.93)
109.3 (104.3-116.6)
116.9 (111.8-128.9)
<0.001
Cholesterol (mmol/L)
2.75 (1.97-3.62)
2.89 (2.22-3.68)
1.97 (1.35-2.79)
<0.001
Total bilirubin (μmol/L)
14.6 (10.1-20.35)
13.9 (9.4-19.65)
17.5 (12.1-22.7)
0.001
Serum urea (mmol/L)
6.36 (4.93-8.64)
5.93 (4.65-7.77)
9.4 (7.11-15.3)
<0.001
Serum creatinine (μmol/L)
71 (51-96.25)
65 (48-82)
133 (97-237)
<0.001
Uric acid (μmol/L)
288 (186.75-388.5)
249 (165-347)
452.5 (360-585)
<0.001
Drugs for reducing ICP
Hypertonic saline (%)
91 (24.33%)
81 (27.46%)
10(12.66%)
0.004
Mannitol (%)
257 (68.72%)
203 (68.81%)
54 (68.35%)
0.938
Glycerol fructose (%)
30 (8.02%)
23 (7.80%)
7 (8.86%)
0.760
Furosemide (%)
55 (14.71%)
39 (13.22%)
16 (20.25%)
0.129
In-hospital mortality (%)
187 (50%)
119 (40.34%)
68 (80.08%)
<0.001
90-day GOS
2 (1-3)
3 (1-4)
1 (1-1)
<0.001
Length of ICU stay (day)
2 (1-16)
2 (0-17)
2 (1-11)
0.384
Length of hospital stay (day)
11 (4-27)
13 (5-28)
6 (3-14)
0.001
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.
